Department of Pharmacology and Chemical Biology, Drug Discovery Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA.
J Pharmacol Exp Ther. 2010 Aug;334(2):627-33. doi: 10.1124/jpet.110.167809. Epub 2010 May 19.
The phosphatases of regenerating liver (PRLs) are a unique family of plasma membrane-associated protein tyrosine phosphatases that have been hypothesized to be involved in metastatic cancer. How PRLs control cancer cell migration, invasion, and proliferation remains largely unknown. In the current study, we demonstrate a role for PRL-1 in the regulation of filamentous actin dynamics, which could promote cell metastatic processes. Human A549 non-small-cell lung cancer cells stably expressing wild-type PRL-1 exhibited a 60% increase in migration and a 3-fold increase in invasion. Cells expressing catalytic mutants of PRL-1 (C104S and D72A) lacked increased cell migration and invasion, indicating that these phenotypic changes required PRL-1 phosphatase activity. In contrast, PRL-1 small interfering RNA decreased in vitro lung cancer cell migration and invasion. The cadherin-catenin complex and dynamic filamentous actin are believed to control cellular invasiveness. Expression of wild-type PRL-1, but not phosphatase-inactive PRL-1 (C104S or D72A), decreased E-cadherin, vinculin, and paxillin expression. Ectopic expression of wild-type PRL-1 increased RhoA levels, which have an important role in actin filament assembly and stabilization of focal adhesion, and decreased activated Cdc42 and Rac. The Rho-associated protein kinase inhibitor, (R)-(+)-trans-4-(1-aminoethyl)-N-(4-pyridyl) cyclohexanecarboxamide dihydrochloride (Y-27632), decreased RhoA activity, actin filament levels, and cellular migration and invasion in PRL-1-expressing cells. These results suggest that PRL-1 could be a productive cancer therapeutic target and support further efforts to identify its substrates.
肝再生磷酸酶(PRLs)是一种独特的质膜相关蛋白酪氨酸磷酸酶家族,据推测其与转移性癌症有关。PRLs 如何控制癌细胞的迁移、侵袭和增殖在很大程度上仍然未知。在本研究中,我们证明了 PRL-1 在调节丝状肌动蛋白动力学方面的作用,这可能促进了细胞的转移过程。稳定表达野生型 PRL-1 的人 A549 非小细胞肺癌细胞的迁移增加了 60%,侵袭增加了 3 倍。表达 PRL-1 (C104S 和 D72A)催化突变体的细胞缺乏增加的细胞迁移和侵袭,表明这些表型变化需要 PRL-1 磷酸酶活性。相比之下,PRL-1 小干扰 RNA 降低了体外肺癌细胞的迁移和侵袭。钙粘蛋白-catenin 复合物和动态丝状肌动蛋白被认为控制细胞侵袭性。表达野生型 PRL-1,但不是无磷酸酶活性的 PRL-1 (C104S 或 D72A),降低了 E-钙粘蛋白、粘着斑激酶和桩蛋白的表达。野生型 PRL-1 的异位表达增加了 RhoA 水平,RhoA 在肌动蛋白丝组装和稳定焦点黏附中有重要作用,并降低了激活的 Cdc42 和 Rac。Rho 相关蛋白激酶抑制剂,(R)-(+)-反式-4-(1-氨基乙基)-N-(4-吡啶基)环己烷甲酰胺二盐酸盐(Y-27632),降低了 RhoA 活性、肌动蛋白丝水平以及 PRL-1 表达细胞的迁移和侵袭。这些结果表明,PRL-1 可能是一种有前途的癌症治疗靶点,并支持进一步努力确定其底物。